CRN Team Vangheluwe improved a cell-based assay for measuring lipid flippase activity and found that TMEM230 strongly inhibits ATP11C-mediated phosphatidylserine transport. 🔗 Read the full #preprint: bit.ly/4h2kiaf

CRN Team Hurley implicated the PITT pathway and VPS13C in tau seeding linked to the endolysosomal network, offering new insight into how pathological tau may spread between brain cells. 🔗 Read the full #preprint: bit.ly/3QZJnrU

CRN Team Harper introduced Q-DOAS, a scalable real-time assay that detects pre-amyloid oligomers and Parkinson’s disease-associated seeds in cerebrospinal fluid without amplification. 🔗 Read the full #preprint: bit.ly/4pirxNy

CRN Team Harper revealed how FBXO7 and PI31 engage the proteasome 20S core particle and how disease-associated variants disrupt proteasome regulation, providing new insight into protein degradation in Parkinsonism. 🔗 Read the full #preprint: bit.ly/4baHQWI

CRN Team Hardy found altered glycosphingolipid metabolism and sex-based differences in GPNMB and lipid levels in Parkinson’s disease, underscoring the need for sex-specific biomarker analyses. 🔗 Read the full #preprint: bit.ly/4vo0wcO

CRN Team Hardy identified APOE- and pathology-dependent pathways to dementia in Lewy body disease, supporting more precise models of progression and patient stratification for therapeutic trials. 🔗 Read the full #publication: bit.ly/4voin3b

CRN Team Hardy showed that GPNMB is released through lysosomal exocytosis in response to lysosomal stress and identified LRRK2 as a key regulator, helping clarify its potential as a marker of lysosomal dysfunction. 🔗 Read the full #publication: bit.ly/4vXQJva

CRN Team Alessi created a cell-type-resolved atlas of brain lysosomes, identifying SLC45A1 as a neuron-specific lysosomal protein and redefining SLC45A1-associated disease as a lysosomal storage disorder. 🔗 Read the full #publication: bit.ly/4vkDX8O

CRN Team Voet used genetically controlled Drosophila models to identify two functional Parkinsonism groups centered on mitochondrial biology and vesicle trafficking/proteostasis, with implications for biomarkers and targeted therapies. 🔗 Read the full #publication: bit.ly/4vcAt8h

CRN Team Rio created a single-cell atlas of 14 familial Parkinson’s disease mutations, revealing mutation-specific signatures and shared disruptions in mitochondrial, endolysosomal, and iron/ferroptosis pathways. 🔗 Read the full #preprint: bit.ly/4eRh48f

CRN Team Rio introduced iSCORE-PD, a collection of 65 isogenic, genome-edited stem cell lines spanning 11 Parkinson’s disease-linked genes to support standardized disease modeling. 🔗 Read the full #publication: bit.ly/4fpKKJD

CRN Team Kirik used machine learning and high-content imaging to identify genotype-specific mitochondrial and lysosomal signatures in patient-derived neurons, supporting cellular stratification and biomarker discovery. 🔗 Read the full #preprint: bit.ly/4eSzd5q

CRN Team Alessi identified age-dependent loss of primary cilia and impaired neurotrophic signaling across vulnerable cell types in G51D α-synuclein mice, pointing to ciliary signaling as a convergent vulnerability in Parkinson’s disease. 🔗 Read the full #preprint: bit.ly/4eQh2NN

Dig into the numbers behind GP2’s latest data release. This release includes an expansion of harmonized environmental and lifestyle clinical data, such as pesticides, alcohol, and smoking, for researchers to further investigate gene-environment interactions. Learn more: bit.ly/444VBlY

#TeamTuesday 🌱 CRN Team Greenamyre is investigating how environmental toxicant exposures may trigger biological processes that drive neurodegeneration and contribute to #Parkinsons heterogeneity. Their work could help identify targets for mitigating post-exposure toxicity. 🔗 bit.ly/4fmkSOS

This month’s Discover ASAP features CRN Team Rio’s Khaja Mohieddin Syed, PhD 🧪 He shares a single-cell atlas of familial #ParkinsonsDisease mutations designed to help researchers compare genetic effects, identify shared disease mechanisms, and generate new hypotheses. 📺 Watch: bit.ly/4eUd9HF

🎥 Check out a new CRN Cloud training video playlist to help researchers navigate the platform, explore available datasets, and begin analyzing shared #Parkinson’s disease omics data. The playlist includes a video on how to perform and share analyses using CRN Cloud datasets: bit.ly/4avLFp9

The 12th GP2 data release is now available. GP2 adds 21,156 additional genotyped participants and 25,046 additional whole-genome sequencing samples, with updates to data pipelines, clinical data including lifestyle and environmental factors, and genomic resources 🧪 bit.ly/444VBlY

#TeamTuesday 🌱 CRN Team Bronstein, one of our new PD Heterogeneity teams, is studying how environmental toxins and genetic factors may shape #Parkinsons progression. Their work uses stem cells and animal models to examine vulnerability to faster progression. 🔗 bit.ly/4waZHVM

A new #publication from CRN Team Alessi maps lysosomal protein composition across major brain cell types, revealing cell-type diversity and identifying SLC45A1 as a neuron-specific lysosomal protein tied to lysosomal dysfunction. 🔗 bit.ly/3QsxZEM

New #preprint from CRN Team Vila explores GABAergic cell clusters in the human midbrain. By identifying inhibitory neurons in the RMTg and RRF, the team lays the groundwork for studying their role in #neurodegenerative diseases. 🔗 Read the full preprint: bit.ly/4vbmGPx

In a new #preprint, CRN Team Harper reveals how LLOMe damages lysosomes. Using cryo-electron tomography, the team found that LLOMe forms amyloid structures that rupture lysosomal membranes, providing new insights into neurodegeneration and lysosomal storage disorders. 🔗: bit.ly/4oKzzy9

🧪 How do environmental exposures, like pesticides and chemicals, shape #Parkinsons risk, and point us toward new therapeutic strategies? Four CRN teams are studying how toxins interact with biology and genetics to drive disease, opening new paths for prevention and treatment. bit.ly/44wpUlv

What determines whether neurons resist or succumb to #ParkinsonsDisease? Discovery Fellows Jonathan Brenton, Kate Brynildsen, Raquel Garza Gomez, and Weiqiang Liu are uncovering how gene regulation, RNA processing, and epigenomic programs shape neuronal resilience ⬇️ 🔗 bit.ly/3PzdS7h

🧬 In a new blog, GP2 shares a three-year strategic roadmap, outlining the next phase that expands research beyond genetic discovery to better understand Parkinson’s disease through the study of genetic risk, biological mechanisms, disease subtypes, and environmental factors. 🔗 bit.ly/4eDthMd

Check out this new #preprint from CRN Team Strick exploring how cardiac-sympathetic activity helps regulate action restraint during reward- and loss-driven decision-making tasks. 🔗 Read the full preprint: bit.ly/4eKazUo

#TeamTuesday 🧫 CRN Team Ulusoy, one of our new Tool Generation teams, is developing labeled antibodies to better detect and measure mitochondrial and oxidative stress pathways in #Parkinsons disease, improving how researchers visualize disease biology. Follow the series👇 🔗 bit.ly/4nGXjD1

🔬 June’s #OpenScience Champion is Elena Coccia (CRN Team Vangheluwe)! Elena’s commitment to open science helped her recent preprint achieve compliance with ASAP’s Open Science Policy. She responded to each compliance report in under three weeks, helping the process move forward quickly.

We’re excited to welcome Jean-Marc Taymans, PhD, from the University of Lille as the June LRRK2 Central #webinar speaker. 👇 Reserve your spot using the link below. 📅 June 25, 2026 ⏰ 1:00 PM ET RSVP: bit.ly/4vJj0oQ

Each fall, ASAP CRN researchers gather for a focused discussion on the cell biology of #ParkinsonsDisease. This year’s conference explored endolysosomal pathways, key disease drivers, and how in-person collaboration helps trainees exchange ideas and advance their work. 🧪 bit.ly/4aQIOak